丁酰胆碱酯酶活性作为ICU患者死亡标志物:个体参与者数据Meta分析
该个体参与者数据Meta分析纳入6个欧洲和南美ICU前瞻性队列共482名危重成人(92.9%脓毒症,院内死亡率39%),评估BChE活性与院内死亡的关系。非幸存者入院BChE更低(汇总AUC 0.72,95%CI 0.65-0.83),第1天BChE每升高100 U/L死亡OR为0.979(95%CI 0.967-0.990,p<0.001),BChE<1615 U/L预测死亡HR 1.69(95%CI 1.11-2.59)。BChE可作为器官功能评分补充,但1615 U/L阈值仅探索性,需前瞻性外部验证。
要点
- 危重成人(92.9%脓毒症)入院BChE越低院内死亡风险越高,汇总AUC 0.72(95%CI 0.65-0.83),判别能力中等。
- 第1天BChE每升高100 U/L,院内死亡OR 0.979(95%CI 0.967-0.990,p<0.001),存在显著ICU天数交互(p=0.029),第4天关联减弱。
- BChE低于1615 U/L者死亡风险更高(HR 1.69,95%CI 1.11-2.59;log-rank p=0.015),但该阈值为探索性,需前瞻性外部验证。
- Meta分析证实BChE与死亡呈独立负相关(每1 sd汇总OR 0.22,95%CI 0.06-0.73;p=0.023)。
- BChE可能补充SOFA、APACHE II等器官功能评分,用于识别高危患者,但不能替代现有评分。
适用人群与场景
- 纳入6个欧洲和南美ICU前瞻性队列的482名危重成人,92.9%合并脓毒症,院内死亡率39%。
诊断标准与关键阈值
- BChE采用Ellman法或Worek法测定,单位统一为U/L。
- BChE低于1615 U/L预测院内死亡风险更高(HR 1.69,95%CI 1.11-2.59;log-rank p=0.015),但原文明确该阈值为探索性、需前瞻性外部验证。
处置流程与药物剂量
- 原文未提及基于BChE的具体处置流程或药物剂量。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征。
研究设计与关键结果
- 研究类型为个体参与者数据Meta分析,纳入6个前瞻性欧洲和南美ICU队列共482名危重成人(92.9%脓毒症,院内死亡率39%)。
- 非幸存者入院BChE更低,汇总AUC 0.72(95%CI 0.65-0.83),DeLong AUC 0.671(95%CI 0.644-0.697),判别能力中等。
- 第1天BChE每升高100 U/L,院内死亡OR 0.979(95%CI 0.967-0.990;p<0.001),存在显著ICU天数交互(p=0.029),第4天关联减弱。
- BChE低于1615 U/L预测更高死亡风险(HR 1.69,95%CI 1.11-2.59;log-rank p=0.015)。
- 随机效应Meta分析证实BChE与死亡呈独立负相关(每1 sd汇总OR 0.22,95%CI 0.06-0.73;p=0.023)。
证据类型、等级与局限
- 证据类型为个体参与者数据Meta分析(观察性前瞻性队列),采用Quality in Prognosis Studies工具评估偏倚风险。
- 局限性:BChE阈值1615 U/L为探索性、需前瞻性外部验证;纳入人群以脓毒症为主(92.9%),外推至非脓毒症ICU人群需谨慎;观察性设计不能推断因果。
对床旁实践的改变
- 对ICU危重成人(尤其脓毒症)可考虑检测入院及动态BChE活性,辅助识别院内死亡高危患者。
- BChE可能补充SOFA、APACHE II等器官功能评分,但不应单独用于决定治疗强度。
- BChE<1615 U/L提示风险增高,但该阈值仅为探索性,不能作为常规决策阈值,需前瞻性外部验证。
- 原文未提及BChE检测可改变具体治疗措施或药物使用。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether butyrylcholinesterase (BChE) activity independently predicts in-hospital mortality in critically ill adults and to derive a prognostic threshold from patient-level data.
DATA SOURCES: Six databases (PubMed, MEDLINE, Embase, Scopus, Web of Science, Cochrane CENTRAL) were searched from inception to data lock. The protocol was registered with PROSPERO (CRD42024558631); reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses of individual participant data (IPD).
STUDY SELECTION: Eligible studies were observational cohorts of critically ill adults measuring BChE by the Ellman or Worek method. Six prospective European and South American ICU cohorts contributed 482 adults (92.9% with sepsis; in-hospital mortality, 39%). Risk of bias was appraised with the Quality in Prognosis Studies tool.
DATA EXTRACTION: Deidentified IPD from corresponding authors and one public repository were checked for integrity, harmonized, and converted to U/L. Variables included demographics, sepsis status, severity indices (Sequential Organ Failure Assessment, Acute Physiology and Chronic Health Evaluation II), and biochemical markers.
DATA SYNTHESIS: Analyses included receiver operating characteristic curves (DeLong area under the curve [AUC], bias-corrected bootstrap), multivariable logistic regression, generalized estimating equation models, Kaplan-Meier and Cox regression, and random-effects meta-analysis (Hartung-Knapp). Admission BChE was lower among non-survivors, with moderate discrimination (pooled AUC, 0.72; 95% CI, 0.65-0.83; DeLong AUC, 0.671; 95% CI, 0.644-0.697). Higher Day-1 BChE was independently associated with lower mortality (odds ratio [OR] per 100 U/L, 0.979; 95% CI, 0.967-0.990; p < 0.001), with a significant ICU day interaction (p = 0.029) and attenuation by Day 4. BChE below 1615 U/L predicted higher mortality (hazard ratio, 1.69; 95% CI, 1.11-2.59; log-rank p = 0.015). Meta-analysis confirmed the inverse association (pooled OR per 1 sd, 0.22; 95% CI, 0.06-0.73; p = 0.023).
CONCLUSIONS: BChE enzymatic activity was an integrative, time-dependent prognostic marker of in-hospital mortality, particularly in sepsis. Reduced ICU admission levels and persistently suppressed trajectories identified higher-risk patients. BChE may complement organ dysfunction scores; the 1615 U/L threshold is exploratory and requires prospective external validation.
参考来源
- Esper Treml R, Grillo ITC, Hrabovska A, et al. Butyrylcholinesterase Activity as a Mortality Marker in ICU Patients: An Individual Participant Data Meta-Analysis. Crit Care Explor. 2026. PMID: 42640628. doi:10.1097/CCE.0000000000001476
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。